116 Efficacy of nivolumab versus pembrolizumab in rmHNSCC. A prospective national multicenter study.

MLA

S, by, Sebastian, et al. “116 Efficacy of Nivolumab versus Pembrolizumab in RmHNSCC. A Prospective National Multicenter Study.” Radiotherapy & Oncology, vol. 192, Mar. 2024, pp. S130–33. EBSCOhost, https://doi.org/10.1016/S0167-8140(24)00489-4.

APA

S, by, S., Gothelf, A., Gyldenkerne, N., Bentzen, J., Andersen, M., Tramm, T., & Eriksen, J. G. (2024). 116 Efficacy of nivolumab versus pembrolizumab in rmHNSCC. A prospective national multicenter study. Radiotherapy & Oncology, 192, S130–S133. https://doi.org/10.1016/S0167-8140(24)00489-4

Chicago

S, by, Sebastian, Anita Gothelf, Niels Gyldenkerne, Jens Bentzen, Maria Andersen, Trine Tramm, and Jesper Grau Eriksen. 2024. “116 Efficacy of Nivolumab versus Pembrolizumab in RmHNSCC. A Prospective National Multicenter Study.” Radiotherapy & Oncology 192 (March): S130–33. doi:10.1016/S0167-8140(24)00489-4.